Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
NCT04232657Phase 2Completed
- Sponsor
- VA Office of Research & Development
- Start
- Mar 2021
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoporosis comparing Romosozumab Treatment with Placebo (2 arms). Primary endpoints: Change in Volumetric Bone Mineral Density at the Distal Femur at 12 months and Change in Volumetric Bone Mineral Density at the Distal Femur after Denosumab at 24 months. Started Mar 2021; status: completed.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT04232657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04232657.